研究预处理中性粒细胞与淋巴细胞比值 (NLR) 和血小板与淋巴细胞比值 (PLR) 在预测卡介苗患者连续膀胱内治疗吉西他滨和多西他赛 (Gem/Doce) 反应中的作用-Guérin (BCG)-初治高危非肌层浸润性膀胱癌 (NMIBC)。对 2011 年 1 月至 2021 年 12 月期间接受膀胱内 Gem/Doce 治疗高危 NMIBC 的 115 名患者进行回顾性分析。计算数据作为中位数（四分位距 [IQR]）或平均值（标准差 [sd]）。进行 Cox 回归分析以确定滴注治疗前中性粒细胞增多、NLR、血小板计数和 PLR 是否可以预测无复发生存期 (RFS) 和总生存期 (OS)。使用 Uno 的 C 统计量估计预测性能。整个队列的中位 (IQR) 随访时间为 23（13-36）个月。 NLR、PLR 和血小板计数的平均值 (sd) 分别为 3.4 (2.3)、142.2 (85.5) 和 225.2 (75.1) × 109/L。 NLR 与 RFS 相关，风险比为 1.32（95% 置信区间 CI 1.19-1.46）。一致性分析显示NLR对RFS具有良好的预测能力（C指数：0.7，P < 0.01）。 PLR 和血小板计数与 RFS 无关，并且不能预测复发。就 OS 而言，这些细胞炎症标志物均未显示任何预测价值。治疗前 NLR 为接受 Gem/Doce 的高危 BCG 初治患者的 RFS 提供了一定的预测准确性。需要进一步的前瞻性试验来验证这一发现。© 2024 BJU International。

To investigate the role of pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in the prediction of response to sequential intravesical therapy, gemcitabine and docetaxel (Gem/Doce), given to patients with bacille Calmette-Guérin (BCG)- naïve high-risk non-muscle-invasive bladder cancer (NMIBC).A retrospective analysis was conducted on 115 patients who received intravesical Gem/Doce for high-risk NMIBC between January 2011 and December 2021. Data were computed as the median (interquartile range [IQR]) or mean (standard deviation [sd]). Cox regression analysis was performed to determine if neutrophilia, NLR, platelet counts, and PLR before instillation therapy were predictive of recurrence-free survival (RFS) and overall survival (OS). Predictive performance was estimated using Uno's C-statistic.The median (IQR) follow-up for the overall cohort was 23 (13-36) months. The mean (sd) values for NLR, PLR and platelet counts were 3.4 (2.3), 142.2 (85.5), and 225.2 (75.1) × 109/L, respectively. NLR was associated with RFS, with a hazard ratio of 1.32 (95% confidence interval CI 1.19-1.46). Concordance analysis showed that NLR had a good ability to predict RFS (C-index: 0.7, P < 0.01). The PLR and platelet count were not associated with RFS and did not predict recurrence. In terms of OS, none of these cellular inflammatory markers showed any prediction value.Pre-treatment NLR provides some predictive accuracy for RFS in high-risk BCG-naïve patients receiving Gem/Doce. Further prospective trials are needed to validate this finding.© 2024 BJU International.